Go back

BioNTech aiming for malaria vaccine with EU help

European Commission and investment bank to “throw weight behind” effort, says von der Leyen

The German biotechnology company BioNTech, which co-developed a widely used vaccine against Covid-19 with the aid of EU funding, has announced that it plans to use the same messenger RNA technology to develop a jab for malaria with the bloc’s support.

Malaria, a disease caused by parasites spread by mosquitoes, kills about 400,000 people every year, mainly in Africa. Over two-thirds of malaria deaths were among children in 2019, according to the World Health Organization (WHO).

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.